Skip to content

Israeli Judicious Antibiotic Prescription Study

Can Change in Physicians' Prescribing Habits Decrease Carriage of Resistant Bacteria in the Community?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01187758
Acronym
IJAP
Enrollment
5700
Registered
2010-08-24
Start date
2002-02-28
Completion date
2007-12-31
Last updated
2010-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic Use, Carriage of Antibiotic Resistant Pathogens

Keywords

antibiotic use, antibiotic prescription, antibiotic resistant S. pneumoniae, MRSA

Brief summary

This study aims to implement judicious antibiotic prescription habits to primary care pediatricians using a multifacet educational intervention and assess two main outcomes: 1) Direct outcome - prescription rates of the physicians. 2)Indirect outcome - carriage of antibiotic resistant bacteria by the treated population, specifically nasopharyngeal S. pneumoniae, nasal S. aureus and rectal E.coli.

Detailed description

Background: Bacterial antibiotic resistance is an increasing problem. Aims: This study aims to implement judicious antibiotic prescription habits among 30 physicians and their treated population as compared to a control group of 30 physicians and their treated population. The outcomes to be measured are: 1. Change in antibiotic prescriptions to the treated patients of the intervention vs. control physicians during the study period (4years). 2. Change in carriage of antibiotic resistant pathogens, specifically nasopharyngeal penicillin resistant S. pneumoniae,nasal MRSA, and rectal quinolone resistant E. coli. Study design: All primary care pediatricians of Hashfela district of Macabbi Healthcare services who will agree to participate will be randomly assigned to an intervention or control group. The intervention group will be led by local leaders (primary care physicians from that district) and will take part in educational activities involving annual workshops and quarterly focus group meetings. The intervention is a multifacet intervention that will include guideline preparation, knowledge building, dealing with uncertainties, etc. The patients of both intervention and control physicians will be screened twice a year for carriage of the bacteria mentioned above. Cross-sectional screening of the treated population will be carried in Summer and winter for 5 consecutive years. Screening will include signing an informed consent, filling a questionnaire and screening with nasal, nasopharyngeal and rectal swabs.

Interventions

BEHAVIORALWorkshops and focus group meetings

Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections

Sponsors

Maccabi Healthcare Services, Israel
CollaboratorOTHER
Sheba Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 5 Years
Healthy volunteers
Yes

Inclusion criteria

* All treated patients of the participating physicians under the age of 5y, who came for any reason for a visit during the study period, who's parents agreed to participate.

Exclusion criteria

The only reason to exclude a child from being recruited was age\>5y or refusal of the parent/child to participate.

Design outcomes

Primary

MeasureTime frameDescription
antibiotic prescription rate of physicians5 yearsAntibiotic prescrption rate at baseline will be compared to changes following the intervention between the 2 groups (control and intervention).

Secondary

MeasureTime frameDescription
Carriage of antibiotic resistant bacteria by treated patients4 yearsEvery summer and winter a crosssectional survey of the treated patients of the control and intervention physicians will be carried out to determine the rate of carriage of penicillin-resistant S. pneumonaie, MRSA and Quinolone-resistant E.coli.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026